Cargando...

Investigational FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in Treatment of Acute Myeloid Leukemia (AML)

INTRODUCTION: Outcomes for the majority of patients with Acute Myeloid Leukemia (AML) remain poor. Over the past decade, significant progress has been made in the understanding of the cytogenetic and molecular determinants of AML pathogenesis. One such advance is the identification of recurring muta...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pemmaraju, Naveen, Kantarjian, Hagop, Andreeff, Michael, Cortes, Jorge, Ravandi, Farhad
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4109297/
https://ncbi.nlm.nih.gov/pubmed/24749672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/13543784.2014.911839
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!